Fig. 6
Both NK cells and CD8+ T cells contribute to the anti-tumor efficacy of PVRIG blockade. a Experimental protocol for murine colon cancer model used in d–g. Mice were injected with isotype-matched control mAb (rat IgG), anti-PVRIG mAb, anti-PVRIG mAb combined with PK136 (anti-NK1.1), anti-PVRIG mAb combined with 53-5.8 (anti-CD8β) or anti-PVRIG mAb combined with PK136 and 53-5.8 intraperitoneally (i.p.) at various time points after injection of 5 × 104 MC38 tumor cells subcutaneously (s.c.) on day 0. b Representative flow plots of splenic NK cells in mice treated with PK136 (anti-NK1.1) antibody or control antibody. c Representative flow plots of splenic CD8+ T cells in mice treated with 53-5.8 (anti-CD8β) antibody or control antibody. d Median tumor size measured at various time points and e overall survival of mice with different treatments (n = 5 (Rat IgG), n = 7 (anti-PVRIG), n = 10 (anti-PVRIG + NK depletion), n = 10 (anti-PVRIG + NK depletion + CD8+ T depletion)). f Median tumor size measured at various time points and g overall survival of mice with different treatments (n = 5 (Rat IgG), n = 7 (anti-PVRIG), n = 10 (anti-PVRIG + CD8+ T depletion), n = 10 (anti-PVRIG + NK depletion + CD8+ T depletion)). h Rag1−/− mice were injected with isotype-matched control mAb (rat IgG) or anti-PVRIG mAb intraperitoneally (i.p.) at various time points after injection of 5 × 104 MC38 tumor cells subcutaneously (s.c.) on day 0. And median tumor size was shown on the right. Data are representative of two independent experiments. Error bars represent means ± s.e.m. Statistical significance was determined using two-way ANNOVA (d, f, h) or Mantel–Cox test (e, g). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001